Business Context and Reporting Period
This Form 8-K, dated December 4, 2022, reports that TherapeuticsMD, Inc. (TXMD) entered into material definitive agreements with Mayne Pharma LLC, a subsidiary of Mayne Pharma Group Limited. The transaction involves the sale of assets and the grant of exclusive licenses for the Company's core product portfolio in the United States.
Key Financial Metrics and Transaction Terms
The filing details a significant asset sale and licensing arrangement rather than standard periodic financial results. Key financial terms include:
- Upfront Cash Consideration: Approximately $153.1 million total at closing, consisting of a $140.0 million base payment and approximately $13.1 million for net working capital.
- Financing Structure: Mayne Pharma will fund the initial $140.0 million payment using cash, existing debt facilities, and a binding commitment from Rubric Capital Management LP for approximately $27.95 million via an unsecured senior convertible note.
- Contingent Milestone Payments:
- $5.0 million if annual U.S. net sales reach $100.0 million.
- $10.0 million if annual U.S. net sales reach $200.0 million.
- $15.0 million if annual U.S. net sales reach $300.0 million.
- Royalties:
- 8.0% on the first $80.0 million of annual net sales.
- 7.5% on annual net sales above $80.0 million.
- Minimum annual royalties of $3.0 million for 12 years (adjusted for inflation at 3%).
- Royalty rate reduces to 2.0% upon patent expiration or generic launch.
- Term: 20 years, after which licenses become royalty-free.
Assets Transferred: The transaction covers Imvexxy, Bijuva, BocaGreenMD, vitaMedMD, and the exclusive license for Annovera.
Material Changes and Strategic Shift
This filing represents a material change in the Company's business model, transitioning from a commercialization entity to a royalty-based model for its primary products. The Company is divesting its commercial operations and manufacturing assets for these products to Mayne Pharma. The filing does not provide comparative revenue, profit, or cash flow metrics for the prior period as this is a current event report, not a periodic financial statement.
Outlook, Risks, and Contingencies
Closing Conditions: The transaction is subject to customary conditions, including the expiration of the Hart-Scott-Rodino (HSR) Act waiting period, absence of material adverse effects, and no legal prohibitions.
Termination Rights:
- Either party may terminate if a court or government entity permanently restrains the transaction.
- The Company may terminate after December 31, 2022 (or January 31, 2023, if financing is extended), if closing has not occurred due to reasons other than Company breach.
- Mayne Pharma may terminate after the same dates if closing has not occurred due to reasons other than Mayne Pharma breach.
Risks: The filing notes that representations and warranties are for risk allocation between parties and should not be relied upon as facts by investors. The transaction is contingent on regulatory approvals and the absence of material adverse effects.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $153.1 million cash receipt.
- Confirm the status of the HSR Act waiting period and any other regulatory approvals.
- Review the terms of the $27.95 million convertible note from Rubric Capital Management LP.
- Monitor the Company's remaining cash position and liquidity post-transaction.
- Assess the Company's future strategic direction and pipeline outside of the divested products.